Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Angioedema Treatment Market Growth Potential: How Will Market Size Shift Through 2030?
The angioedema treatment market has seen rapid expansion in recent years. Its valuation is set to rise from $3.13 billion in 2025 to $3.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this market’s growth can be attributed to elements like emergency allergy management, hospital-based care, the utilization of corticosteroids, the presence of antihistamine options, and the limited availability of highly targeted medications.
The angioedema treatment market is anticipated to experience significant expansion over the coming years, reaching $6.18 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. This projected increase during the forecast period is largely due to advancements in biologic drug development, the rise in genetic testing, the establishment of specialized allergy clinics, enhanced patient education, and a greater emphasis on preventive care. Key developments expected during this period involve a rise in targeted bradykinin therapies, an increase in hereditary angioedema treatments, the broader implementation of emergency treatment protocols, improved understanding of diagnostics, and a focus on proactive therapeutic strategies.
Get A Free Sample Report With In-Depth Market Insights:
Angioedema Treatment Market Growth Catalysts And Demand Drivers
The angioedema treatment market is anticipated to expand moving forward due to an uptick in the occurrence of rare diseases. Rare diseases are defined as medical conditions that affect a very small segment of the population, often presenting with limited therapeutic options and considerable health consequences. The increasing prevalence of rare diseases is attributed to breakthroughs in genetic testing and diagnostic technologies, enabling healthcare professionals to detect and accurately diagnose conditions previously overlooked, thereby leading to a higher reported frequency. Angioedema treatment proves beneficial for rare diseases like hereditary angioedema by delivering targeted therapies that assist in preventing and managing severe swelling episodes, thus improving patient outcomes. For instance, in November 2024, the Food and Drug Administration, a US-based federal agency, reported that over 7,000 rare diseases impacted more than 30 million individuals in the United States. Therefore, the growing incidence of rare diseases is fueling the expansion of the angioedema treatment market.
Angioedema Treatment Market Breakdown By Product Type And Application
The angioedema treatment market covered in this report is segmented –
1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema
2) By Route Of Administration: Injection, Oral
3) By End Use: Hospitals, Clinics, Research Organizations
Subsegments:
1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies
2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors
3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management
4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics
Angioedema Treatment Market Trends Shaping Long-Term Demand
Leading companies in the angioedema treatment market are concentrating on developing innovative therapies, such as subcutaneous injections, to provide patients suffering from acute hereditary angioedema (HAE) attacks with more convenient and rapid relief. Subcutaneous injections involve administering medication into the fatty tissue just beneath the skin for slow and steady absorption into the bloodstream. As an illustration, in April 2025, CSL Limited, an Australia-based biotechnology company, launched ANDEMBRY (garadacimab), a novel, fully human monoclonal antibody treatment aimed at preventing acute attacks in individuals with hereditary angioedema (HAE). ANDEMBRY stands as the first pre-filled pen designed for once-monthly subcutaneous administration, offering a convenient long-term prophylactic alternative. This drug functions by inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the cascade that leads to angioedema. It signifies a substantial advancement in HAE management by delivering effective, patient-centric disease control.
Angioedema Treatment Market Company Landscape And Competitive Strategy
Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.
View The Full Angioedema Treatment Market Report:
Angioedema Treatment Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model